The Relevance of Drug–drug Interactions in Clinical Practice: The Case of Concomitant Boosted Protease Inhibitors plus Alpha-1 Blocker Administration

Alfuzosin monograph. (Accessed 4 July 2017.) Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021287s011lbl.pdf.

Tamsulosin monograph. (Accessed 4 July 2017.) Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020579s016lbl.pdf.

Silodosin monograph. (Accessed 4 July 2017.) Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001209/WC500074185.pdf.

Fusco F. , Palmieri A. , Ficarra V. α1-Blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol 2016; 69: 1091–1101.

Yamada S. , Ito Y. , Tsukada H. α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics. Br J Clin Pharmacol 2011; 72: 205–217.

Franco-Salinas G. , de la Rosette J.J. , Michel M.C. Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. Clin Pharmacokinet 2010; 49: 177–188.

Wilde M.I. , Fitton A. , McTavish D. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs 1993; 45: 410–429.